In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
- Pathology Technology Australia’s key priorities in the coming years
- Current local capability in pathology technology compared to other countries
- How the health system supports change and adoption of pathology technology
- How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
- Observations in the Strengthening Medicare Taskforce Report
And lastly Dean looks towards the Federal Budget this year and in 2024 for the adoption of currently unfunded pathology tests, that could alter pathology as a cost centre to one that saves the health system considerable money.
You Might also like
-
Bridging the orthodontic knowledge gap
In recent years, the orthodontic sector has been growing rapidly due to success in B2C marketing and companies like Invisalign reaching the consumer, but there has also been a lack of knowledge sharing among general dental practitioners and specialists.
General dentists require mentorship and guidance from orthodontists to feel confident in providing orthodontic treatment to their patients, ultimately improving the quality of care in the community.
-
Addressing Pharmacy challenges at home and abroad
Paul Sinclair’s progression through the ranks of the International Pharmaceutical Federation (FIP) demonstrates the impact and influence he’s had in representing the pharmacy profession on a global scale. In this Australian Health Journal interview, Paul talks about the 4 themes in the upcoming FIP Congress in Brisbane this month. He also talks about the challenges facing pharmacy with remuneration, professional service delivery and the workforce coming out of the COVID era.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.